Raleigh Capital Management Inc. Sells 558 Shares of Sanofi (NASDAQ:SNY)

Raleigh Capital Management Inc. lowered its position in Sanofi (NASDAQ:SNY) by 1.7% in the 3rd quarter, Holdings Channel reports. The firm owned 32,841 shares of the company’s stock after selling 558 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Sanofi were worth $1,893,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SNY. Boston Partners grew its holdings in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after purchasing an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the period. Mondrian Investment Partners LTD raised its stake in shares of Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Down 2.3 %

Shares of NASDAQ:SNY opened at $53.66 on Tuesday. The company has a market capitalization of $136.16 billion, a PE ratio of 29.16, a P/E/G ratio of 1.57 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The business’s fifty day simple moving average is $56.13 and its 200-day simple moving average is $51.62.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. As a group, equities research analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SNY shares. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.